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Salicylic acid (SA) is a critical plant hormone that is involved in many processes, includ-
ing seed germination, root initiation, stomatal closure, floral induction, thermogenesis, 
and response to abiotic and biotic stresses. Its central role in plant immunity, although 
extensively studied, is still only partially understood. Classical biochemical approaches 
and, more recently, genome-wide high-throughput screens have identified more than 
two dozen plant SA-binding proteins (SABPs), as well as multiple candidates that have 
yet to be characterized. Some of these proteins bind SA with high affinity, while the 
affinity of others exhibit is low. Given that SA levels vary greatly even within a particular 
plant species depending on subcellular location, tissue type, developmental stage, and 
with respect to both time and location after an environmental stimulus such as infection, 
the presence of SABPs exhibiting a wide range of affinities for SA may provide great 
flexibility and multiple mechanisms through which SA can act. SA and its derivatives, 
both natural and synthetic, also have multiple targets in animals/humans. Interestingly, 
many of these proteins, like their plant counterparts, are associated with immunity or 
disease development. Two recently identified SABPs, high mobility group box protein 
and glyceraldehyde 3-phosphate dehydrogenase, are critical proteins that not only serve 
key structural or metabolic functions but also play prominent roles in disease responses 
in both kingdoms.
Keywords: salicylic acid, salicylic acid-binding proteins, salicylic acid derivatives, plant immunity, animal immunity 
and inflammation, disease, common plant and animal targets
iNTRODUCTiON
In plants, salicylic acid (SA) was viewed as a relatively unimportant secondary metabolite until 
the late twentieth century, when Raskin and coworkers revealed its involvement in signaling 
thermogenesis (1) and our group (2), together with Métraux and colleagues (3), demonstrated its 
importance in activating disease resistance. Today, a Google search for the “number of papers on 
salicylic acid and plant disease resistance” lists ~59,000. Many, if not most, of these studies confirm 
SA’s central role in immunity, principally against biotrophic and hemibiotrophic pathogens.
In contrast, the importance of SA and its derivatives (collectively called salicylates) as pharma-
cological agents has long been appreciated. Salicin, the SA derivative that is the active ingredient 
in willow bark, was isolated in 1828; however, Hippocrates, the father of medicine, reportedly 
prescribed willow bark to reduce fever and the pain of childbirth in the fifth millennium B.C. High 
levels of salicylates have been detected in several plant species besides willow. For example, mead-
owsweet contains both salicin and methyl salicylate (MeSA), another medicinal derivative that also 
FiGURe 1 | Metabolism of salicin and methyl salicylate to salicylic 
acid (SA). The SA core is highlighted in pink.
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is known as the highly fragrant oil of wintergreen. In animals/
humans, these “prodrugs” are converted to SA upon digestion 
(Figure 1) (4, 5). The sources and chemical structures of several 
useful natural salicylates are shown in Table  1. Not only have 
medicinal plants rich in salicylates been used worldwide in many 
different cultures for thousands of years but also they continue 
to be used today. In this regard, the most famous SA derivative, 
acetyl SA, is a relative “new comer” as it was first synthesized by 
Bayer and Company in 1897 and subsequently sold under the 
trade name aspirin. Interestingly, the name SA is derived from 
the Latin name for white willow (Salix alba), while the term 
aspirin is derived from meadowsweet (Spiraea ulmaria).
ONe OR A Few ReCePTORS vS. 
MULTiPLe TARGeTS
The current view is that hormones in plants, as well as in ani-
mals, exert their effect(s) by binding to one or a small number 
of receptors. Is SA’s mechanism(s) of action consistent with 
this dogma? The answer to this question is currently unclear. 
One or more members of the non-expressor of pathogenesis-
related protein (NPR) family were proposed to function as 
SA receptors in plants (23, 24). The molecular mechanism(s) 
through which SA mediates NPR1’s function as a co-activator 
of immunity-induced transcriptional reprograming is cur-
rently unresolved. While the identification of NPR proteins as 
SA targets is a major step toward elucidating SA’s mechanisms 
of action in defense against microbial pathogens, the upregula-
tion of some plant immune responses, including expression of 
a subset of defense-related genes, is mediated via a pathway(s) 
that is dependent on SA, but independent of NPR1 (25, 26). 
Moreover, it is not known whether NPR1/NPR3/NPR4 is 
involved in mediating SA’s effects on other plant processes, 
including growth and development and/or response to abiotic 
stress (27). Thus, NPR proteins may not function as SA recep-
tors in the traditional sense.
The identification of almost 30 SA-binding proteins 
(SABPs) using traditional purification approaches (28–32) and 
genome-wide, high-throughput screens (33, 34) (http://bioinfo.
bti.cornell.edu/SA2010/), further argues that SA exerts its effects 
via more than one or a few receptors. Given that SA-binding alters 
the activity of many of these SABPs, several difficult questions 
must be considered: should all identified SABPs listed in Table 2 
be promoted to SA receptor status? Alternatively, should the level 
of SA-binding affinity be used as a criterion, with only those SABPs 
displaying high affinity qualifying for receptor status? The latter 
scenario presents additional concerns, as it is unclear what dis-
sociation constant (Kd) value should serve as the cutoff, and who 
should decide it? In addition, the affinities of the reported NPR 
receptors overlap those of several SABPs. For example, the MeSA 
esterase SABP2 from tobacco and its Arabidopsis ortholog MES9 
have high affinities for SA (apparent Kd = 0.092 and ~0.200 μM, 
respectively) (31, 32, 35), which are similar to those of NPR1 
(Kd = 0.140–0.190 μM) (24, 34) and NPR4 (Kd = 0.046 μM) (23). 
By contrast, the SA affinity displayed by NPR3, the other reported 
SA receptor, is considerably lower (Kd = 1 μM) and approaches 
those of catalase (Kd =  15.5 μM) (36) and carbonic anhydrase 
(Kd = 3.7 μM) (30). We propose that proteins which bind hor-
mones (or other ligands) and as a result have altered function or 
activity be termed “targets” of their corresponding hormone. The 
term receptor could be applied to a subset of these targets that 
meet additional criteria. For example, classic receptors for water-
soluble hormones, which cannot diffuse through the plasma 
membrane, span this membrane in order to detect extracellular 
hormones at the cell surface and initiate downstream intracellular 
signaling (e.g., G protein-coupled receptors and the enzyme-
linked receptors) (37, 38). On the other hands, many receptors 
for steroids, which readily diffuse through the plasma membrane, 
are located intracellularly, and directly regulate gene transcrip-
tion upon complex formation with their cognate hormone (39). 
Given the many targets through which SA appears to mediate its 
effects on diverse physiological and pathological plant processes, 
we suggest that this represents a paradigm shift for how, at least, 
some hormones function. Furthermore, this novel paradigm may 
prove applicable to other plant hormones and perhaps even some 
animal hormones.
Of the various SABPs whose SA-binding affinities have 
been determined, their Kd values span from 0.046 to 15.5 μM. 
Consistent with this 300-fold range, SA levels in plants can vary 
dramatically (Table 3). Not only do they differ between various 
plant species but they also can vary within an individual plant 
depending on the tissue type, subcellular compartment, and 
developmental stage. In addition, SA levels can vary with respect 
to the time and/or location after reception of an (a)biotic stress, 
such as pathogen infection (Table 3). Thus, we hypothesize that 
SA exerts its multitudinous effects by differentially interacting 
with various SABPs depending on their affinity for SA, their loca-
tion, and the local SA concentration. Our analyses of SABP2, 
a MeSA esterase, and its role in signaling systemic defense 
responses in tobacco are consistent with this mechanism (45). 
Following pathogen infection, SA levels increase dramatically in 
the inoculated leaves, where much of it is converted to biologi-
cally inactive MeSA by SA/benzoic acid methyl transferase; once 
the SA concentration becomes sufficiently high, it binds in the 
active site of SABP2 and inhibits SABP2’s ability to convert MeSA 
TABLe 1 | List of useful salicylates present in various plants.
Salicylates Structure Plant source Use Reference
Salicina Aspen (Populus tremula) Analgesic, antipyretic, 
anti-inflammatory
(6–9)
Black haw (Viburnum prunifolium)
White willow (Salix alba)
Meadowsweet (Spiraea ulmaria)
Methyl salicylatea Birch tree (Betula lenta)
Mango (Mangifera indica)
Meadowsweet (Spiraea ulmaria)
Wintergreen (Gaultheria rocumbens)
Guelder-rose (Viburnum opulus)
Analgesic (joint and 
muscular pain), fragrance
(9–13)
Amorfrutinsb Indigo bush (Amorpha fruticosa)
Licorice (Glycyrrhiza foetida)
Antidiabetic, anti-cancer, 
anti-inflammatory
(14–18)
Benzyl salicylate Cananga tree (Cananga odorata)
Mango (Mangifera indica)
Wintergreen (Gaultheria rocumbens)
Fragrance, UV light absorber (11, 12, 19, 20)
Cis-3-hexenyl salicylate Mango (Mangifera indica)
Wintergreen (Gaultheria rocumbens)
Fragrance (11, 12)
4-Hepten-2-yl salicylate Ashoka (Saraca indica) Fragrance (21, 22)
Isoamyl salicylate Wintergreen (Gaultheria rocumbens) Fragrance (12)
The salicylic acid core is highlighted in pink.
aSalicin and methyl salicylate are converted into SA (see Figure 1 for details).
bArmofrutin 1 is shown as a representative structure of various amorfrutins.
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back into SA (45). The resultant increase in MeSA facilitates its 
translocation to the distal, uninfected tissue. Since SA levels in the 
distal tissue are too low to inhibit SABP2, the transported MeSA 
is converted to active SA, which then induces and/or primes vari-
ous systemic defense responses. Similarly, the interplay between 
SA, NPR1, and NPR3/4 fine-tunes NPR1 homeostasis in a SA 
concentration-dependent manner, which determines the levels 
and types of plant defense responses during pathogen infec-
tion (23, 27). The presence of SABPs exhibiting a wide range of 
affinities for SA, combined with the varying SA levels found in 
specific subcellular compartments, in different tissues, at differ-
ent developmental stages, or during responses to environmental 
cues, provides tremendous flexibility and multiple mechanisms 
through which SA can exert its effects. Unfortunately, little is 
known about the concentrations and distributions of SA at the 
cellular and/or subcellular levels, because measurements are 
generally made on total tissue extracts. Thus, there is a pressing 
need for novel in vivo detection methods of SA (e.g., fluorescent 
probes) (46, 47) to provide a greater, more detailed understand-
ing of SA functions in mediating the activities of its target or 
receptor proteins.
MULTiPLe TARGeTS OF SA AND iTS 
DeRivATiveS iN HUMANS
The first SA targets identified in humans were the cyclooxyge-
nases COX1 and COX2. These enzymes convert arachidonic 
acid, the major plasma membrane fatty acid in animals, into 
prostaglandins. Prostaglandins have hormone-like activities that 
induce pain, inflammation, swelling, and fever. Notably, these are 
TABLe 2 | List of plant SA-binding proteins (SABPs).
Protein name Plant species Genetic locus of 
Arabidopsis SABPs
interaction with SA plays  
a role in plant immunity
Reference
Catalase Tobacco Yes (28)
Ascorbate peroxidase Tobacco Yes (29)
Methyl salicylate esterases (tobacco SABP2  
and Arabidopsis AtMES1, 2, 4, 7, and 9)
Tobacco, Arabidopsis At2g23620 Yes (31, 32)
At2g23600
At2g23580
At2g23560
At4g37150
Carbonic anhydrase (SABP3) Tobacco, Arabidopsis At3g01500 Yes (30, 40)
NPR1 Arabidopsis At1G64280 Yes (24, 34)
NPR3 Arabidopsis At5G45110 Yes (23)
NPR4 Arabidopsis At4G19660 Yes (23)
Glutathione S-transferases PHI  
(GSTF2, 8, 10, and 11)
Arabidopsis At4g02520 (33)
At2g47730
At2g30870
At3903190
Ketoglutarate dehydrogenase E2 subunit (KGDHE2) Arabidopsis, tomato At5g55070 Yes (33, 41)
Thimet oligopeptidases (TOP1 and 2) Arabidopsis At5g65620 Yes (42)
At5g10540
Glyceraldehyde 3-phosphate dehydrogenases  
(GAPDHA1, A2, C1, and C2)
Arabidopsis At3g26650 Yes (43)
At1g12900
At3g04120
At1g13440
Thioredoxin M-type 1 (TRX-m1) Arabidopsis At1g03680 (34)
Tripeptidyl peptidase II (TPP2) Arabidopsis At4g20850 (34)
Serine hydroxyl methyltransferase 4 (SHM4) Arabidopsis At4g13930 (34)
Lipoxygenase 2 (LOX2) Arabidopsis At3g45140 (34)
Glutathione peroxidase (GPX2) Arabidopsis At2g31570 (34)
Glutamine synthetase (GSR2) Arabidopsis At1g66200 (34)
Hydroxypyruvate 2 (HPR2) Arabidopsis At1g79870 (34)
Ribulose bisphosphate carboxylase small subunit 1A 
(RBCS1A)
Arabidopsis At1g67090 (34)
UDP-d-glucose/UDP-d-galactose 4-epimerase 2 (UGE2) Arabidopsis At4g23920 (34)
High mobility group B3 (HMGB3) Arabidopsis At1g20696 Yes (44)
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the same symptoms that are relieved by ingestion of salicylate-
rich medicinal plants, SA, or acetyl SA (aspirin). In the early 
1970s, Vane and coworkers discovered that aspirin irreversibly 
inhibits COX1 and COX2 by acetylating a serine near the active 
site, which prevents access of the arachidonic acid substrate to the 
active site (62, 63). This hallmark discovery has dominated the 
field ever since and supports the prevailing view in the biomedi-
cal community of how aspirin works. However, this hypothesis 
cannot explain how salicylate-rich medicinal plants, which have 
been used worldwide for millennia, and SA, which was used 
extensively for half a century before the synthesis of aspirin, are 
able to treat pain, inflammation, and fever. Naturally occurring 
salicylates and SA are only weak inhibitors of COX1 and COX2, 
as they cannot acetylate them (63), and yet SA has most of the 
same pharmacological effects as aspirin. Moreover, aspirin is 
rapidly converted to SA in the human body with a half-life of 
about 20 min (64, 65). In contrast, plasma SA levels after aspirin 
ingestion rapidly increase and are sustained for more than 12 h 
(66). These facts argue that there must be additional SA targets 
besides the cyclooxygenases. During the past three decades, 15 
additional potential targets of aspirin, SA, and/or SA prodrugs 
(Figure 2) have been identified (Table 4). Several of these SA/
aspirin targets are associated with inflammation, including 
tumor necrosis factor alpha (TNFα), nuclear factor-kappa-B 
(NF-κB), inhibitor of NF-κB kinase subunit beta (Iκκ-β), and 
high mobility group box 1 (HMGB1), while others regulate 
energy metabolism, such as adenosine monophosphate-activated 
protein kinase (AMPK) and peroxisome proliferator-activated 
receptor gamma (PPARγ). For example, sulfasalazine (see 
Figure 2 for its structure) blocks TNFα-induced T-cell activation 
by inhibiting the binding of TNFα to its receptor (67). Aspirin 
and sodium salicylate are proposed to inhibit transcription factor 
NF-κB-mediated pro-inflammatory signaling by inhibiting Iκκ-β 
kinase activity, which induces degradation of inhibitory protein 
of NF-κB (IκB) by phosphorylation (68, 69). Unfortunately, the 
levels of aspirin or SA needed to alter the activities of many of 
these potential targets are very high and are likely to have toxic 
side effects in humans.
PLANTS AND ANiMALS SHARe SeveRAL 
SA TARGeTS
Using a high-throughput screen, we recently identified several 
members of the Arabidopsis glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) family, including GAPDHC1, as 
SABPs. In  both  plants and animals, GAPDH plays a central 
role in  glycolysis; in addition, some family members are 
TABLe 3 | endogenous salicylic acid levels in different plants.
Plant Sample (treatment) SA (free) Conjugated SAa Reference
Cucumber (Cucumis sativus) Leaf (No) ~0.04 μg/g FW – (3, 48)
Leaf (P.l.) ~0.9 μg/g FW ~8.0 μg/g FW
Systemic leaf (P.l.) ~0.32 μg/g FW ~3.0 μg/g FW
Leaf (TNV) ~0.125 μg/g FW ~0.75 μg/g FW
Systemic leaf (TNV) ~0.1 μg/g FW ~0.1 μg/g FW
Phloem sap (No) ~0.1 μg/mL –
Phloem sap (C.l.) ~0.9 μg/mL –
Phloem sap (TNV) ~0.4 μg/mL –
Tobacco (Nicotiana tabacum) Leaf (No) 0.05–0.3 μg/g FW 0.02–0.1 μg/g FW (2, 49–51)
Leaf (TMV) 2.0–20.0 μg/g FWb 1–75 μg/g FW
Systemic leaf (TMV) ~1.5 μg/g FW ~1.5 μg/g FW
Phloem sap (No) <0.01 μg/mL <0.01 μg/mL
Phloem sap (TMV) ~0.25 μg/mL –
Rice (Oryza sativa) Leaf (No) ~10 μg/g FWc – (52)
Leaf (P.s.) ~10 μg/g FW –
Arabidopsis (Arabidopsis thaliana) Leaf (No) 0.07–1.0 μg/g FW 0.15–4.0 μg/g FW (53–56)
Leaf (P.s.) 1.5–3.0 μg/g FW 5.0–8.0 μg/g FW
Systemic leaf (P.s.) ~0.2 μg/g FW ~0.6 μg/g FW
Potato (Solanum tuberosum) Leaf (No) 0.2–2 μg/g FW 5.0–15.0 μg/g FW (57–59)
Leaf (A.a.) 8–10 μg/g FW ~4 μg/g FW
Stem (No) ~1 μg/g FWd ~1.5 μg/g FW
Pepper (Capsicum annuum) Leaf (No) ~0.2 μg/g FW ~0.8 μg/g FW (60)
Leaf (X.c.) ~2 μg/g FW ~2 μg/g FW
aSA conjugated to glucose as SA 2-O-β-d-glucoside (SAG) or salicylate glucose ester (SGE) (61).
bSee figure 2 in Enyedi et al. (49) for distribution of endogenous SA around necrotic lesions induced by TMV.
cFree SA level varies among different varieties of rice plants (52).
dSee figure 1 and 4 in Navarrea and Mayoa (58) for endogenous SA levels in different potato organs and in potato plants during different seasons, respectively.
No, no treatment; P.l., Pseudomonas lachrymans; TNV, tobacco necrosis virus; C. l., Colletotrichum lagenarium; P.s., Pseudomonas syringae; TMV, tobacco mosaic virus;  
A.a., arachidonic acid; X.c., Xanthomonas campestris; FW, fresh weight.
FiGURe 2 | Chemical structures of SA and its synthetic and natural derivatives. The SA core is highlighted in pink. *This amorfrutin was called amorfrutin 1 in 
Weidner et al. (17) and FN2 in Choi et al. (14).
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usurped by invading viruses to facilitate their replication. 
For example, efficient replication of tomato bushy stunt virus 
(TBSV) requires binding of GAPDH to the 3′ end of the 
negative-strand RNA template for synthesis of  the positive 
strand, which is translated or packaged into the virion (79). 
In collaboration with Peter Nagy’s group, we showed that SA 
inhibits TBSV replication by binding to GAPDH and thereby 
preventing its binding to the negative-strand RNA template in 
the replication complex (Figure 3) (43). Similarly, SA binding 
to human GAPDH suppresses its ability to bind the poly (U) 
tract of the 3′ non-coding region of the genome of hepatitis C 
virus (HCV), which is required for efficient replication and/
or translation (Tian and Klessig, unpublished results). It is 
interesting to note that glycyrrhizin, a compound derived 
from Glycyrrhiza foetida (common name licorice), also binds 
to human GAPDH and alters its activities much like SA – see 
below (14). Moreover, glycyrrhizin has anti-HCV activity 
and has been used for decades in Japan to treat chronic HCV 
TABLe 4 | List of human proteins targeted by salicylates.
Protein name Salicylate Reference
Arachidonate 
5-lipoxygenase (ALOX5)
5-aminosalicylic acid, sulfasalazine (70)
Tumor necrosis factor alpha 
(TNFα)
Sulfasalazine (67)
Cyclooxygenase-1 (COX-1) Aspirin (63, 71)
Cyclooxygenase-2 (COX-2) Aspirin, sodium salicylate (63, 71, 72)
Nuclear factor-kappaB 
(NF-κB)
Aspirin, sodium salicylate (69)
Cathepsin A (CTSA) Aspirin (73)
Inhibitor of nuclear factor-
kappa-B kinase subunit beta 
(Iκκ-β)
Aspirin, sodium salicylate (68)
Ribosomal S6 kinase 2 
(RSK2)
Aspirin, salicylic acid (74)
Adenosine monophosphate-
activated protein kinase 
(AMPK)
Sodium salicylate (75)
Peroxisome proliferator-
activated receptor gamma 
(PPARγ)
Amorfrutins (17)
Ferrochelatase (FECH) Salicylic acid (76)
Acetyltransferase p300 
(P300)
Salsalate, salicylate (77)
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH)
Salicylic acid, amorfrutins B1 and 
FN2, acetyl 3-aminoethyl salicylic 
acid, 5-aminosalicylic acid
(14)
High mobility group box 1 
(HMGB1)
Salicylic acid, amorfrutin B1, 
acetyl 3-aminoethyl salicylic acid
(15)
Cyclin-dependent kinase 2 
(CDK2)
Aspirin, salicylic acid (78)
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infection (80, 81). Together, these findings suggest that SA or 
its more potent derivatives (see below) might be useful treat-
ments for HCV infection.
In addition to GAPDH’s role in viral infection, it is a major 
suspect in several neurodegenerative diseases in humans, includ-
ing Huntington’s, Parkinson’s, and Alzheimer’s diseases (88). The 
central role human GAPDH plays in neurodegeneration was 
established by the pioneering work of Ishitani and Chuang (89), 
and later by Snyder and coworkers (90). The latter study also pro-
vided evidence for a novel cell death cascade involving GAPDH, 
nitric oxide, and the E3 ubiquitin ligase called Seven in absentia 
homolog (Siah) (91). In brief, oxidative stress conditions can 
lead to elevated levels of nitric oxide, which cause S-nitrosylation 
of GAPDH’s catalytic cysteine 150. This inactivates GAPDH’s 
glycolytic activity and induces its interaction with Siah, whose 
nuclear localization signal enables the complex to enter the 
nucleus (91). Since the complex between Siah and GAPDH 
stabilizes this E3 ubiquitin ligase, turnover of Siah’s nuclear 
target proteins is increased, which in turn leads to cell death. 
Underscoring the significance of this GAPDH/Siah cell death 
cascade is the demonstration that the anti-Parkinson’s disease 
drug deprenyl, which reduces neuronal cell death in both in vitro 
and in vivo models, prevents S-nitrosylation of GAPDH, blocks 
the GAPDH–Siah interaction, and inhibits GAPDH nuclear 
translocation (90).
Using recombinant human GAPDH, we demonstrated that 
SA not only binds this protein but also suppresses its ability to 
translocate to the nucleus and induce cell death at low micromo-
lar concentrations (14). Several natural and synthetic derivatives 
of SA that bind GAPDH more strongly than aspirin/SA also were 
identified; importantly, their greater binding affinity is correlated 
with enhanced inhibition of GAPDH’s nuclear translocation 
and cell death induction. The natural SA derivatives, called 
amorfrutins, are produced by G. foetida, while the synthetic 
derivative, acetyl 3-aminoethyl SA, was designed based on the 
structure of the amorfrutins, as well as the ability of other SA-like 
compounds to very tightly bind GAPDH and HMGB1, our other 
newly identified SA/aspirin target (15).
In parallel, our high-throughput screens used to identify 
human SABPs uncovered HMGB1. HMGB1 is the most 
abundant non-histone protein in the nucleus. It binds to the 
minor groove of DNA and plays a central role in condensing 
DNA, which affects nucleosome packing, transcription, and 
DNA replication, repair, and recombination. In addition, when 
HMGB1 is passively released to the extracellular milieu due to 
tissue damage or necrosis, it functions as a damage-associated 
molecular pattern (DAMP) to activate the innate immune 
system (92, 93). Extracellular HMGB1 triggers inflammation by 
recruiting immune-related cells involved in fighting infection 
and repairing damaged tissue. In addition, it stimulates these 
recruited immune-related cells to express genes encoding pro-
inflammatory signaling proteins called cytokines. The resulting 
inflammation protects damaged tissue against infection and pro-
motes healing. In some circumstances, however, inflammation 
is not properly controlled or it persists (non-resolved); this can 
contribute to the pathogenesis of many inflammation-associated 
diseases, such as arthritis, atherosclerosis, lupus, inflammatory 
bowel disorders, and sepsis, and certain cancers, such as colorec-
tal and mesothelioma cancers.
We have discovered that SA binds to HMGB1, thereby 
blocking its pro-inflammatory activities (15). It does so at 
concentrations (low micromolar) far lower than those required 
to suppress the enzymatic activity of COX1 and COX2. Notably, 
we found that HMGB1 induces the expression of Cox2, as 
well as cytokine genes, and that low levels of SA suppress this 
induction. Thus, SA, such as aspirin, can suppress inflamma-
tory responses mediated by COX2, but SA does so by inhibiting 
COX2 synthesis, rather than its activity. The discovery that 
HMGB1’s pro-inflammatory activities are inhibited by low 
levels of SA provides one likely explanation for the protective 
effects of low-dose aspirin usage.
Analyses of amorfrutin B1 and acetyl 3-aminoethyl SA 
revealed that they bind to HMGB1 in the same site as SA but do 
so with higher affinity. Similar to their greater potency in sup-
pressing GAPDH activity, these compounds were 40- to 70-fold 
more effective than SA at inhibiting HMGB1’s pro-inflammatory 
activities. The existence of natural and synthetic SA deriva-
tives that are even more potent than aspirin/SA at suppressing 
HMGB1’s and GAPDH’s disease-associated activities argues that 
there is significant potential for the development of SA-based 
drugs with improved efficacy and, possibly, fewer negative side 
effects.
All eukaryotic cells, including plants, have HMGB1-related 
proteins. Arabidopsis has eight HMGB-type proteins, including 
FiGURe 3 | Salicylic acid (SA) affects both plant and human health, in part through common targets such as GAPDH and HMGB proteins. In plants, SA 
is a key hormone that modulates immune responses; in humans, it is the major metabolite of aspirin. (A) SA binds to human GAPDH and suppresses its 
translocation from cytoplasm to nucleus and the resulting cell death (14). (B) SA binds to GAPDH and suppresses its participation in viral replication. In plants, 
GAPDH binding to the minus (−) RNA strand of tomato bush stunt virus (TBSV) promotes plus (+) RNA strand synthesis by the viral RNA-dependent RNA 
polymerase p92 (82). SA inhibits the interaction between plant GAPDH and the (−) RNA strand of TBSV, thereby reducing viral replication (left panel) (43). In humans, 
Petrik et al. (83) reported that human GAPDH binds to the poly (U) tract of genomic hepatitis C virus (HCV) RNA, while SA and aspirin were subsequently shown to 
suppress HCV replication (84, 85). We found that SA inhibits human GAPDH binding to poly (U), suggesting that SA has a similar mechanism of action for inhibition 
of HCV and TBSV (right panel, Tian and Klessig, unpublished results). (C) SA inhibits the DAMP activities of HMGBs in humans (left panel) (15) and in plants (right 
panel) (44). Extracellular human HMGB1 functions as a damage-associated molecular pattern (DAMP or alarmin). SA binds to HMGB1, thereby inhibiting the 
pro-inflammatory activities of reduced and disulfide-bonded HMGB1 (hHMGB1RE and hHMGB1SS, respectively). C–X–C chemokine receptor 4 (CXCR4) recognizes 
the heterocomplex of hHMGB1RE and C–X–C motif-containing chemokine 12 (CXCL12) to induce cell migration, while the toll-like receptor 4 (TLR4) binds the 
heterocomplex of hHMGB1SS and myeloid differentiation factor 2 (MD-2) (86) to activate expression of Cox2 and pro-inflammatory cytokine genes (IL-6 and TNFα). 
SA blocks these pro-inflammatory pathways (15). In plants, HMGB3 functions as a DAMP. Extracellular HMGB3 activates pattern-triggered immunity responses, 
including MAPK activation (MPK3 and MPK6), defense-related gene expression (WRKYs, PR-1, and PDF1.2), and callose deposition. The regulatory receptor-like 
kinases BAK1 and/or BKK1 are required for HMGB3 signaling through a yet to be discovered receptor. This figure is modified from Klessig (87).
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HMGB3, which is present in the cytoplasm and in the nucleus. 
Given that human HMGB1 is a prototypic DAMP in animals 
(92, 93) and that its DAMP activities are inhibited by SA bind-
ing (15), we asked whether Arabidopsis HMGB3 (i) functions 
as a DAMP, (ii) binds SA, and (iii) exhibits reduced DAMP 
activity following SA binding (44). We found that introduc-
tion of HMGB3 into the extracellular space (apoplast) induced 
innate immune responses, including callose deposition, MAPK 
activation, defense gene expression, and enhanced resistance 
to a necrotrophic fungal pathogen. Like its animal counterpart, 
HMGB3 bound SA and this binding suppressed its ability to 
induce innate immune responses and protect against pathogen 
infection.
wHY MiGHT ANiMALS HAve SO MANY 
SA TARGeTS
Further research will likely uncover additional SA targets and 
help clarify which are responsible for SA’s beneficial therapeutic 
activity, as well as its negative side effects. The potentially large 
number of SA targets, combined with the multiple pharmaco-
logical effects mediated by SA and its prodrug aspirin, and the 
widespread use of aspirin and/or natural SA derivatives (which 
our studies suggest are the basis for at least some traditional 
medicines) suggest that much remains to be done in order to 
elucidate SA’s mechanisms of action. We predict that SA (and 
aspirin) exerts its effects in humans via multiple mechanisms of 
action that are mediated by a variety of targets. Such a scenario 
would be consistent with our discovery that plants contain more 
than two dozen proteins through which SA regulates immunity 
and other plant processes. The majority of animals eat plants, 
which exposes them to SA and its derivatives on a regular basis. 
Indeed, vegetarians contain similar levels of SA and its urinary 
metabolite salicyluric acid as individuals taking low-dose aspirin 
(94). However, dietary intake of SA appears to account for only 
a modest portion of the serum and urinary salicylates present in 
animals. Analyses of germ-free animals indicate that serum SA is 
not synthesized by gastrointestinal microbes. Rather, studies with 
13C-labeled benzoic acid suggest that animals synthesize endog-
enous SA in large part using this precursor. Benzoic acid and its 
salts are found in high amounts in some fruits and vegetables, 
and thus it might contribute to the modest variability in serum 
SA associated with diet. Also, benzoic acid may be synthesized 
endogenously in animals using phenylalanine as a precursor. 
Based on these findings, Paterson and coworkers (94) suggested 
that it is “increasingly likely that SA is a biopharmaceutical with a 
central, broadly defensive role in animals as in plants.” Low levels 
of SA, resulting from dietary intake of SA and endogenous synthe-
sis from benzoic acid/benzoate, might have led to the emergence 
of multiple SA targets in animals. If future studies confirm this 
hypothesis, it is highly likely that a variety of SA targets common 
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to both kingdoms will be identified. Their characterization will 
not only help elucidate the mechanisms through which SA exerts 
its varied effects but also should provide clues for devising highly 
effective strategies to control pathological processes in plants and 
animals.
CONCLUSiON
Salicylic acid acts through many targets, rather than a few 
receptors, to mediate its many effects on diverse physiological 
and pathological processes in plants. The presence of SABPs 
exhibiting a wide range of affinities for SA, combined with the 
varying SA levels found in specific subcellular compartments, 
in different tissues, at different developmental stages, or dur-
ing responses to environmental cues, provides tremendous 
flexibility and multiple mechanisms through which SA can 
exert its effects in plants. Animals have multiple targets of SA 
and its derivatives besides cyclooxygenases COX1 and COX2, 
which are the two major targets of aspirin. The discovery that 
HMGB1’s pro-inflammatory activities are inhibited by low 
levels of SA provides one likely explanation for the protective 
effects of low-dose aspirin usage. The existence of natural and 
synthetic SA derivatives that are even more potent than aspirin/
SA at suppressing HMGB1’s and GAPDH’s disease-associated 
activities argues that there is significant potential for the devel-
opment of SA-based drugs with improved efficacy and, possibly, 
fewer negative side effects. Low levels of SA, resulting from 
dietary intake of SA and endogenous synthesis from benzoic 
acid/benzoate, might have led to the emergence of multiple SA 
targets in animals, as in plants, some of which are common to 
both kingdoms.
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